Market research
UBX Unity Biotechnology Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 3.25
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US91381U2006
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 3.25
- Dividend yield
- Not available
- Beta
- 1.06
About
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the UBX discussion.
5 years, 4 months ago
Unity Biotechnology, Inc is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Unity Biotechnology, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.5% to $-94K since the same quarter in the previous year.
Finally, its free cash flow fell by 3.6% to $-17M since the same quarter in the previous year.
Based on the above factors, Unity Biotechnology, Inc gets an overall score of 2/5.